Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide with or without Epoetin beta and G-CSF in low/intermediate-1 risk myelodysplastic syndrome
2008-002195-10Phase 2Active
- Sponsor
- HOVON
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lenalidomide in myelodysplastic syndrome (MDS) (2 arms), sponsored by HOVON. Primary endpoint: Hematological improvement. Started Dec 2008; status: active.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2008-002195-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002195-10.